Aptose Biosciences (NASDAQ:APTO) Coverage Initiated at StockNews.com

Research analysts at StockNews.com started coverage on shares of Aptose Biosciences (NASDAQ:APTOGet Free Report) (TSE:APS) in a report issued on Thursday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Separately, HC Wainwright decreased their target price on Aptose Biosciences from $7.00 to $2.00 and set a “buy” rating on the stock in a research report on Wednesday.

View Our Latest Research Report on Aptose Biosciences

Aptose Biosciences Trading Down 22.1 %

NASDAQ:APTO opened at $0.19 on Thursday. The company has a market capitalization of $3.44 million, a P/E ratio of -0.05 and a beta of 1.26. Aptose Biosciences has a 12 month low of $0.13 and a 12 month high of $2.91. The business’s 50-day moving average is $0.38 and its 200 day moving average is $0.61.

Institutional Investors Weigh In On Aptose Biosciences

A hedge fund recently bought a new stake in Aptose Biosciences stock. Armistice Capital LLC acquired a new stake in shares of Aptose Biosciences Inc. (NASDAQ:APTOFree Report) (TSE:APS) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 1,713,000 shares of the biotechnology company’s stock, valued at approximately $1,300,000. Armistice Capital LLC owned 9.46% of Aptose Biosciences at the end of the most recent reporting period. 26.62% of the stock is owned by hedge funds and other institutional investors.

About Aptose Biosciences

(Get Free Report)

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.

Further Reading

Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.